Cyril Camaro, Department of Cardiology, theme Vascular damage, received a ZonMw grant of EUR 450k for a study of patients suspected of acute coronary syndrome (ACS).The ARTICA study (“Acute Rule out of non ST-segment elevation acute coronary syndrome in the (pre)hospital setting bye HEART score assessment and a single point of care Troponin”) is a multicenter randomized trial to assess the cost-effectiveness and efficacy of ambulance triage with further general practitioner management compared to standard hospital admission in patients with symptoms suggestive for non-ST elevation ACS, but with low risk characteristics (low HEART score and negative troponin). This study will be executed in strong partnership with our networkpartner CWZ and local Ambulance Services.
Cyril Camaro is interventional cardiologist / academic researcher and member theme Vascular damage.
Related news items
Handbook of biomarkers and precision medicine a new publication by Alain van Gool12 July 2019
Alain van Gool published a new handbook on biomarkers and applications in (pre)clinical drug development for precision medicine.read more
The real impact of menstrual complaints on work and school productivity8 July 2019
Menstrual period symptoms may be linked to nearly nine days of lost productivity every year, through presenteeism, suggests the largest study of its kind, published in the journal BMJ Open. But the real impact on women and society is underestimated and poorly appreciated, say the researchers.read more
Walking for science Research by Radboud university medical center and Radboud University during the Vierdaagse (Four Day Marches)5 July 2019
The Vierdaagse is a unique opportunity to conduct research into physical activity and healthy lifestyle.read more
Prostate cancer theranostics imaging, surgical guidance, and targeted photodynamic therapy5 July 2019
In Theranostics, Mark Rijpkema and colleagues present the development of a novel multimodal tracer that targets both preoperative imaging, surgical guidance, and targeted photodynamic therapy of PSMA-expressing prostate cancer.read more